Pharmaceuticals, Biotechnology and Life Sciences
Skipanon Brand Seafoods LLC of Warrenton, Oregon is voluntarily recalling ALL LOTS, ALL SIZES of ALL Skipanon brand seafoods canned products because it has the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illness or death. Consumers are warned not to use the product even if it does not look or smell spoiled.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health.
TF Supplements of Houston, TX, is voluntarily recalling RHINO 7 3000 capsules packaged in a bottle containing six capsules and Rhino 7 Platinum 3000 Capsules packaged in a single blister packs hang card count.
Eli Lilly and Company and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy.
Quantum Pharma has signed an out-licensing agreement with a German pharmaceutical company for its first licensed product, a cholecalciferol 20 000IU capsule, marketed in the UK under the brand name Aviticol.
Physiomics plc, the Oxford, UK based systems biology company has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4th large pharma customer for this service.
The U.S. Food and Drug Administration (FDA) has today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Eli Lilly has acquired worldwide rights to Locemia’s intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin.
Johnson & Johnson has started a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies.
Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.